To test this model, we followed the strategy of Beltran et al. 19, who developed a CRISPR-dCas9 system to position RNA elements in the periphery of the transcription start site of a PRC2-targeted gene, CDKN2A, in Malignant Rhabdoid Tumor (MRT) cells and test their effect on gene expression (Fig. 5a). Here, CDKN2A is linked to rhabdoid tumor.